Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program

Rhea-AI Summary

Agenus (NASDAQ: AGEN) announced a conference call on May 18, 2021, at 8:30 a.m. ET to discuss a global licensing agreement with Bristol Myers Squibb. This agreement marks a significant milestone for Agenus, which focuses on immuno-oncology, developing therapies to activate the immune response against cancer. Interested parties can join the call via dial-in numbers or through the live webcast accessible on the company's website. Agenus aims to enhance patient outcomes in cancer treatment through its diverse therapeutic pipeline.

Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET

LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today.

Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International); Conference ID: 6545558.

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gmikyrev.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

What is the purpose of the Agenus conference call on May 18, 2021?

The conference call aims to discuss the global licensing agreement between Agenus and Bristol Myers Squibb.

How can I listen to the Agenus conference call?

You can listen to the conference call via dial-in numbers or through the live webcast on the Agenus website.

What time is the Agenus conference call scheduled for on May 18, 2021?

The conference call is scheduled for 8:30 a.m. ET on May 18, 2021.

What is Agenus' focus in the immuno-oncology field?

Agenus focuses on developing therapies that engage the immune system to fight cancer, including checkpoint antibodies, cell therapies, and vaccines.

What is the stock symbol for Agenus?

Agenus trades under the stock symbol AGEN on NASDAQ.